Testing Amiloride to Slow Down Chronic Kidney Disease Progression with Proteinuria Randomized, Double-Blind, Placebo-Controlled Crossover Trial in Adults

What this Trial Is About

Researchers are evaluating the effects of amiloride in adults with chronic kidney disease CKD and proteinuria. This randomized, placebo-controlled, double-blinded crossover trial aims to see if amiloride can protect the kidneys filtering barrier, reduce inflammation, lower albumin in the urine, and preserve kidney function. The study focuses on how amiloride might inhibit harmful processes independent of blood pressure changes. Participants receive amiloride 5 mg twice daily for 7 days or a matching placebo twice daily for 7 days, followed by a 2-3 week washout period before switching treatments. Blood and urine samples are collected before and after each treatment period. The study also monitors electrocardiograms, body composition, blood pressure, and body weight during the trial. Throughout the study, researchers measure urinary markers of kidney injury and inflammation, including urinary C3a, soluble C5-9, KIM-1, and NGAL. Secondary measures include urine albumincreatinine and proteincreatinine ratios, along with home blood pressure readings. Participants are closely monitored for safety, and the total study duration involves two treatment periods separated by washout intervals.

Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease